Celldex Therapeutics ( NASDAQ:CLDX ) has recently emerged as a frontrunner in this arena, unveiling compelling results from its innovative treatment for chronic hives. The consequential findings have ignited a surge in investor enthusiasm, propelling the biotech stock to its highest point since October 2021.
Celldex's ( NASDAQ:CLDX ) breakthrough revolves around...
Key Highlights:
Positive Phase 2 Study: Celldex Therapeutics revealed positive outcomes from a Phase 2 study of Barzolvolimab, focusing on patients with moderate to severe chronic spontaneous urticaria (CSU) refractory.
Well-Tolerated and Favorable Safety Profile: Barzolvolimab demonstrated general well-tolerance and exhibited a favorable safety profile in the...
